D
iabetes is enormously important in older adults. Its incidence and prevalence rise until late life, resulting in a high burden. 1 Moreover, impaired glucose tolerance markedly elevates cardiovascular disease (CVD) risk in older adults. 2 Glycemia is a balance of glucose production and usage and insulin secretion and sensitivity. Several other factors influence these processes, including expansion of fat mass, sarcopenia, and inflammation, all central components of aging. 3 Similarly, outcomes of diabetes, such as albuminuria, overlap with the organ fibrosis and dysfunction that characterizes aging. 4 Thus, different combinations of disease risk factors and downstream physiological processes can lead to phenotypic heterogeneity. With the growth of precision medicine in elderly adults, 5 recognition of heterogeneity may improve targeting of drug and lifestyle recommendations. Cluster analysis has particular strengths in identifying natural variations or groupings of individuals. Because it is driven by clustering across individuals and not by outcomes, it fosters an unbiased approach to examining "natural" metabolic phenotypes and how they relate to prognosis. We have previously shown that cluster analysis can reduce large numbers of interrelated variables into recognizable patterns for diet and structural brain abnormalities in older adults, 6, 7 and it has informed the underlying pathophysiology of metabolic disorders for decades. [8] [9] [10] [11] To understand metabolic heterogeneity in older adults more fully, we conducted cluster analysis of several biomarkers measured in the Cardiovascular Health Study (CHS), a population-based longitudinal study of CVD in 5,888 community-dwelling older adults. We derived clusters using metabolic parameters and examined risk of cardiovascular, glycemic, and geriatric outcomes associated with each cluster.
RESEARCH DESIGN AND METHODS

Study Population
CHS is a prospective study of men and women aged 65 and older recruited from Medicare eligibility lists in 4 U.S. communities. 12, 13 In 1989-90, 5,201 participants were recruited and examined (the original cohort); in 1992-93, 687 additional African-American participants were recruited.
The study design, objectives, and collection and measurement techniques have been previously published. 12, 13 Examinations generally included standardized questionnaires and physical and laboratory examinations. Followup contact occurred every 6 months, alternating between telephone calls and clinic visits through 1999 and telephone calls thereafter. Participants provided written informed consent upon enrollment. The institutional review boards at all centers approved the original recruitment and its ongoing conduct.
Metabolic Parameters
A schematic illustration of measurements is shown in Supplemental Figure S1 . We used the 1996-97 examination as the baseline for these analyses, because it was the only examination in which the original and African-American cohorts underwent oral glucose tolerance testing (OGTT) or urine collection. Participants underwent fasting phlebotomy, random urine collection, direct height and weight measurement, and (for participants who did not use glucose-lowering medication) a standard 75-g OGTT with 2-hour postload phlebotomy.
We selected candidate measures from available covariates in three groups-measures of glycemic status, factors associated with impaired glycemic regulation, and direct consequences of hyperglycemia. The first group included fasting and postload serum glucose and plasma insulin and fasting C-peptide. The second included body mass index (BMI) and CRP, and the third included cystatin-based estimated glomerular filtration rate (eGFR), urinary albuminto-creatinine ratio (ACR), carboxymethyl lysine (CML; an advanced glycation endproduct (AGE)), 14 and the N-terminal propeptide of procollagen III (PIIINP, a measure of AGE-related fibrosis). 15 For clustering, we included participants at the 1996-97 examination who were not taking glucose-lowering medication and reported fasting for at least 8 hours. We subsequently included participants with treated diabetes as a comparison group. Of the 4,708 participants alive in 1996-97, we excluded 1,035 who did not attend the clinic visit, 590 who were ineligible, 213 with missing measurements, and 639 who declined the OGTT, leaving a final sample of 2,231. Included participants were approximately 1.5 years younger and more likely to be female and to report good to excellent health than those excluded.
Cardiovascular and Functional Outcomes
Central committees adjudicate all cases of myocardial infarction, stroke, and death in CHS. Details of adjudication and confirmation of these events have been published. 16, 17 In these analyses, our primary composite outcome included incident myocardial infarction, stroke, and coronary or cerebrovascular mortality.
We examined two measures of subclinical vascular disease taken in 1998-99. Carotid ultrasonography was conducted to evaluate intima-media thickness (IMT) for the internal and common carotid arteries. 18 Ankle-brachial index (ABI) was assessed bilaterally in standardized fashion, 19 using the ratio of the average of 2 blood pressure measurements in the right arm and the lower of 2 measurements in the right and left legs.
We included 2 functional measures assessed every 6 months during follow-up. Disability was defined as selfreported inability to perform at least 1 activity of daily living (ADL; walking around home, getting out of bed or chair, dressing, bathing, eating, toileting). Mobility limitation was defined as reported difficulty walking up 10 steps or walking half a mile on 2 consecutive contacts or at the last contact.
For incident CVD, disability, and mobility limitation, we excluded individuals with prevalent CVD (angina pectoris, myocardial infarction, bypass surgery, angioplasty, congestive heart failure, stroke, transient ischemic attack), disability, or mobility limitation at baseline in analyses of the respective outcome.
Prevalent and Incident Diabetes
We determined the prevalence of impaired fasting glucose or impaired glucose tolerance and untreated diabetes in 1996-97 using current American Diabetes Association cutpoints. 20 To evaluate the duration of these states, we examined their prevalence in 1992-93 in the full cohort and in 1989-90 in the original cohort.
We ascertained incident cases of diabetes from 1996-97 forward using multiple complementary methods. These included fasting glucose measurements in 1998-99 and 2005-06 and incident use of glucose-lowering medication ascertained annually in a validated medication inventory. 21 We also identified individuals with Medicare claims for diabetes (International Classification of Diseases, Ninth Revision, code 250.xx) using a stringent modification of the standard algorithm, 1 which required 2 inpatient or 3 outpatient claims to define cases.
Using the 0-and 120-minute time points available from the 1996-97 OGTT, we estimated insulin sensitivity in 1996-97 using the modified Matsuda index. 22, 23 To estimate the insulin response, we used a previously proposed equation. 24, 25 For comparison, we examined estimated insulin sensitivity and response using the same equations in the subset of participants who underwent OGTT in 1989-90.
Covariates
We categorized smoking as current, former, or never. Physical activity was estimated using a modified Minnesota Leisure-time Physical Activity scale. 26 Alcohol intake was reported as the quantity and frequency of wine, beer, and spirits and categorized as 0, 1, 2 to 7, 8 to 14, and more than 14 drinks per week. Hypertension was defined as systolic blood pressure of 140 mmHg or greater, diastolic pressure of 90 mmHg or greater, or reported history of hypertension with use of antihypertensive medication.
Circulating adiponectin levels were measured in 1992-93 and albumin levels in 1996-97. Self-reported health was ascertained yearly as poor, fair, good, very good, or excellent. Frailty, as initially defined in CHS, 27 was assessed in 1996-97.
Statistical Analysis
We used Stata version 12 (Stata Corp., College Station, TX) for analyses. We first conducted K-means cluster analysis to identify clusters of individuals with similar values on all 11 primary metabolic variables. We Winsorized right-skewed variables at the upper 99th percentile (setting values above the 99th percentile to that value) to minimize the influence of outlying values. 28 We log-transformed CRP and ACR to reduce their skew. To ensure comparability, we treated the 11 variables as standardized measures (in standard-deviation units from their mean). We chose the number of clusters a priori to be between 4 and 8 to ensure reasonably robust sample sizes and avoid overfitting. We used the Calinski-Harabasz pseudo-F index, which is a ratio of the variance between clusters over the variance within them, to inform selection of the number of clusters; we then compared the solutions with the highest index values (which maximize distance between clusters) for plausibility and interpretability. 29 We examined demographic and clinical characteristics of the clusters using chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables. We determined the prevalence and duration of untreated prediabetes and diabetes in each cluster in 1996-97 and 4 and 7 years earlier in the original cohort.
We conducted multivariable Cox proportional hazards analyses to examine associations with mortality, incident CVD, disability, mobility limitation, and diabetes and examined the proportional hazards assumption using Schoenfeld residuals. We adjusted for age, sex, race, smoking, physical activity, alcohol consumption, and hypertension; in analyses of mortality, we also adjusted for baseline CVD. Follow-up time was measured from baseline to the event of interest, if it occurred; if not, participants were censored at date of death, loss to follow-up, or December 31, 2010, whichever came first. To avoid violations of the proportional hazards assumption, we further truncated follow-up time at 10 years for incident CVD and 8 years for incident disability.
Lastly, we examined ABI and carotid IMT using linear regression. We limited ABI analyses to participants with an ABI less than 1.4. We standardized common and internal carotid IMT measurements, averaged them, and present results for each cluster in standard-deviation units. For both subclinical measures, we adjusted for covariates similar to those used in the Cox analyses.
RESULTS
Identification of Clusters
Five-and 6-cluster solutions yielded metabolic clusters with the highest Calinski-Harabasz pseudo-F index values (286 and 271). Figure 1 and Supplemental Figure S2 illustrate the 6-cluster solution. Table 1 shows characteristics of each of cluster according to clustering variables. Cluster A had the lowest glucose, insulin, and albuminuria levels and the highest eGFR. Clusters B and C had high fasting and postload insulin levels; Cluster C also had high fasting and postload glucose levels. Cluster D had high glucose levels without corresponding high insulin levels. Cluster E was had low eGFR, in the chronic kidney disease (CKD) range, and high ACR, CML, and PIIINP levels. Cluster F had high CRP levels. For comparison, the 5-cluster solution tended to group all hyperglycemic individuals into a single cluster, regardless of insulin levels. The 7-cluster solution (Calinski-Harabasz pseudo-F index value 249) identified a cluster with high CML but no other distinguishing characteristics.
Clinical, Demographic, and Glycemic Characteristics Table 1 shows the clinical and demographic characteristics of participants according to cluster. The mean age was nearly 80, and approximately 40% were male. Albumin levels, a negative acute-phase reactant, were lowest in Cluster F. Frailty was most prevalent in Cluster E. Table 2 illustrates the prevalence of prediabetes and diabetes in the six clusters. Virtually all participants with untreated diabetes were in Cluster D. Likewise, virtually all participants in that cluster had diabetes at study baseline and had had impaired glucose tolerance or frank diabetes 7 years earlier.
Insulin sensitivity estimated using the modified Matsuda index were lower in Clusters B and C than in A (Table 2 ). In contrast, estimated insulin secretion was profoundly lowest in Cluster D and highest in Clusters B and C. Seven years earlier, estimated insulin secretion had been highest in those 2 clusters and was similar to values in 1996-97; values in Cluster D in 1989-90 were again lowest but were much closer to those in the other clusters at that time. Table 3 provides adjusted hazard ratios for risk of incident American Diabetes Association-defined diabetes during follow-up. Consistent with results in Table 2 , risk of incident diabetes was 14 times as high in individuals in Cluster D as in those in Cluster A. Risk was graded in the remaining clusters, decreasing from Cluster D to Cluster F, but all had significantly higher risk than Cluster A.
Mortality, CVD, Disability, and Mobility Limitation Table 3 also shows death, incident CVD, incident disability, and incident mobility limitation according to cluster. In general, risks of CVD and death were highest and roughly similar in magnitude in Clusters C, D, and E. In contrast, Clusters B and F did not have clearly greater risk of death or CVD than Cluster A. This general pattern also extended to incident mobility limitation but differed for incident disability, for which risk was not statistically significantly greater in Cluster D but was roughly double in Cluster C. Participants taking diabetes medications were more likely to die (adjusted hazard ratio (aHR) = 1.32, 95% confidence interval (CI) = 1.17-1.49) and develop CVD (aHR = 1.45, 95% CI = 1.14-1.84), disability (aHR = 1.41, 95% CI = 1.18-1.68), and mobility limitation (aHR = 1.51, 95% CI = 1.28-1.77) than the metabolically healthy Cluster A.
Subclinical Atherosclerosis
Supplemental Table S1 shows differences in ABI and carotid IMT according to cluster. In both cases, Cluster A had the best values, but the two measures differed in their relationships with other clusters. For ABI, Cluster D had the lowest values, and only Cluster E also differed significantly from Cluster A. In contrast, every cluster had greater IMT than Cluster A, with a particularly strong association for Cluster C.
Supplemental Table S2 summarizes the relative associations between the clusters and clinical and subclinical outcomes.
CONCLUSION
In this prospective cohort study, we defined 6 metabolic clusters of individuals. These clusters were associated with all outcomes that we evaluated and corresponded well with recognizable metabolic signatures, despite the unsupervised learning inherent in this approach. Specifically, these clusters were notable for relative metabolic health (Cluster A), high glucose and insulin suggestive of insulin resistance (Cluster B), higher glucose and insulin suggestive of greater insulin resistance (Cluster C), unrecognized diabetes with low insulin (Cluster D), CKD (Cluster E), and isolated inflammation (Cluster F).
An attractive advantage of unsupervised methods such as cluster analysis is their ability to identify natural groupings of individuals and, in so doing, to test the validity of traditional clinical phenotypes. In this regard, our results generally match established pathophysiology. In particular, Cluster D was associated with an impaired insulin response to a glucose load and was virtually synonymous with diabetes, with nearly all individuals having longstanding glucose intolerance. Although this appropriately reflects the long-established recognition that type 2 diabetes occurs when insulin secretion fails to meet the increasing demands of insulin resistance, 30 ,31 estimated insulin secretion was dramatically lower in that cluster. Given that estimated insulin secretion had not been nearly as depressed 7 years earlier, our results suggest that interim loss of b-cell function is a central feature of diabetes that occurs late in life, presumably reflecting progressive pancreatic exhaustion and possibly the superimposition of islet-cell destruction from late-life autoimmunity or amyloid deposition. 32, 33 Our results also identify two clusters (Clusters B and C) in which estimated insulin resistance was higher than in Cluster A; as expected, these were associated with much greater risk of diabetes. Cluster C, in which glucose and insulin levels were much higher, was prospectively (37) 143 (34) 51 (43) 59 (46) 162 (52) 214 (42) Black, n (%) 91 (12) 70 (17) 17 (14) 19 (15) 40 (13) 88 (17) Current smoker, n (%) 62 (8) 28 (7) 3 (3) 8 (6) 25 (8) 40 ( (30) 74 (18) 16 (14) 23 (18) 49 (16) 120 (23) Waist, cm, mean (85) 340 (81) 85 (72) 106 (82) 228 (73) 414 (81) Frailty, n (%) Not frail 338 (51) 136 (37) 28 (27) 31 (28) 67 (26) 179 (40) Intermediate frail 303 (45) 199 (54) 59 (58) 67 (60) 149 (57) 227 (51) Frail 27 (4) 34 (9) 15 (15) 13 (12) 45 (17) 40 (9) Comorbidities, n (%) Hypertension 366 (50) 278 (66) 85 (72) 91 (71) 212 (68) 302 (59) Coronary heart disease 121 (16) 88 (21) 37 (31) 35 (27) 105 (33) 97 (19) Congestive heart failure 28 (4) 26 (6) 12 (10) 13 (10) 48 (15) 20 (4) Cerebrovascular disease 41 (6) 31 (7) 19 (16) 13 (10) 43 (14) 32 (6) Albumin, gm/dL, mean associated with CVD and mortality at least as strongly as treated diabetes, but Cluster B, with slightly lower levels, was not. This offers the possibility that lifestyle modification similar to that found to be effective in older adults in the Diabetes Prevention Program 34 may have long-term benefits in terms of CVD and death if it can forestall progression of insulin resistance.
Cluster E contained participants with multiple features of CKD and an average eGFR in the range of moderate CKD. These individuals also had high PIIINP levels, a marker of systemic fibrosis unlikely to be elevated because of low renal clearance alone. 35 This elevation implicates renal fibrosis in the pathogenesis of kidney disease in older adults. 36 Although this cluster was associated with all outcomes studied, these participants were at highest risk of death, consistent with previous observations in CHS regarding the strong prognostic value of cystatin C and albuminuria. 37, 38 Hazard ratios derived from proportional hazards regression models adjusted for age, sex, race, smoking, physical activity, alcohol consumption, and hypertension; mortality analyses further adjusted for prevalent CVD. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of participants taking diabetes medications were 1.32 (1.17-1.49) for death, 1.45 (1.14-1.84) for CVD, 1.41 (1.18-1.68) for disability, and 1.51 (1.28-1.77) for mobility limitation. Maximal follow-up time was 14.5 years for death, diabetes, and mobility limitation, 10 years for CVD, and 8 years for disability.
Cluster F, characterized by isolated inflammation, had higher CRP levels and lower albumin levels, suggesting that this cluster indeed had systemic inflammation. This cluster was associated with greater incident disability and diabetes but not higher rates of CVD or death, despite the positive association between inflammation and short-term mortality found in earlier analyses. 39 One possible explanation is that this cluster had higher BMI and inflammation, which have competing associations with mortality in CHS. 40 Our results have potential implications for mitigating metabolic risk in late life. By identifying recognizable, physiologically plausible clusters of elderly adults, our results enable targeting of preventative strategies to specific physiological states. For example, the CKD group might be appropriate for novel antifibrotic therapies, 41 and emerging efforts to reduce inflammation directly 42 might be targeted toward the isolated inflammation cluster.
Cluster analysis and other data-reduction approaches have long been used to study chronic metabolic disorders. Recognition that insulin resistance clustered with other CVD risk factors 9, 10 led to the adoption of metabolic syndrome as a discrete entity, but these approaches have also identified subsets of individuals with type I diabetes with diverse prognoses 43 and disentangled those risk factors that are central or peripheral to the metabolic syndrome. 8, 44 Our approach extends previous efforts that defined the metabolic syndrome to older adults and new metabolic biomarkers.
Specific limitations warrant discussion. CHS has measured numerous metabolic factors that are uncommon in large cohort studies such as postload glucose and insulin and CML, but glycosylated hemoglobin was measured only at the North Carolina site only in 1989-90, and erythrocytes with which to measure it were not stored, although glycosylated hemoglobin was unrelated to subclinical or clinical CVD in CHS. 45, 46 Similarly, total cholesterol but not its subfractions were available in 1996-97, limiting our ability to describe clusters on the basis of all metabolic syndrome components, although associations between lipid fractions and CVD are modest in CHS. 47 The CHS OGTT included only fasting and 2-hour measurements, and hence estimated values for insulin sensitivity and secretion rely upon equations that are imperfectly associated with criterion-standard approaches and have not been specifically validated in external populations. Likewise, no insulinogenic index to integrate insulin secretion and sensitivity was available. 48 Cluster analysis requires judgment regarding the numbers of clusters and candidate variables. We included several variables measured concurrently that are intimately connected with glycemic regulation. Nonetheless, the wealth of CHS data necessarily means that other variables were not included. We also examined multiple potential solutions and found that 6 clusters yielded meaningful information without arbitrary distinctions, but confirmation of our findings in cohorts with similar data is desirable.
In summary, even in late life, older adults can be separated into meaningful metabolic clusters defined according to insulin resistance, impaired insulin response, kidney disease, and inflammation, which are associated with risk of death, CVD, disability, and diabetes. Efforts to reduce development of these risk factors in middle age may yield large benefits in the health of Americans living into their eighth decade and beyond.
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